HC Wainwright Boosts BridgeBio Pharma (NASDAQ:BBIO) Price Target to $49.00
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price upped by HC Wainwright from $43.00 to $49.00 in a research ...
Nasdaq4d
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug
BridgeBio Pharma, Inc. BBIO recently announced that it obtained FDA approval for its pipeline candidate acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy (ATTR ...
Nasdaq4d
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use
BridgeBio Pharma BBIO recently received FDA approval for its pipeline candidate acoramidis for the treatment of adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related ...
Nasdaq5d
BridgeBio price target raised to $49 from $43 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on BridgeBio (BBIO) to $49 from $43 and keeps a Buy rating on the shares. Acoramidis received regulatory approval with the label underscoring ...
Nasdaq5d
BridgeBio FDA approval ‘significant clearing event,’ says Citi
Citi analyst David Lebowitz keeps a Buy rating on BridgeBio (BBIO) with a $45 price target after the FDA granted approval for Attruby for ATTR-CM. The drug’s label was in line with expectation ...
BridgeBio Pharma (NASDAQ:BBIO) Given New $45.00 Price Target at Bank of America
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price increased by Bank of America from $42.00 to $45.00 in a ...
Research Analysts Set Expectations for BBIO FY2027 Earnings
Equities research analysts at Leerink Partnrs cut their FY2027 EPS estimates for shares of BridgeBio Pharma in a research ...
44,623 Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Purchased by Intech Investment Management LLC
Intech Investment Management LLC acquired a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) in the 3rd ...
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Acquired by Massachusetts Financial Services Co. MA
Massachusetts Financial Services Co. MA lifted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 23.3% in ...
ETF Daily News4d
BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $48.00 at Scotiabank
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price raised by Scotiabank from $45.00 to $48.00 in a report issued on Monday morning,Benzinga reports. The brokerage currently has a sector ...